Quantification Of Cardiometabolic Risk In Obesity: Use Of Artificial Neural Network | 14768
Journal of Obesity & Weight Loss Therapy
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Risk factors that promote cardiovascular disease and/or type 2 diabetes are often cluster, including obesity,
insulin resistance, hyperglycemia, lipid and lipoprotein disturbances and hypertension. Obesity has a profound
impact on the cardiovascular disease development: the increase of fat mass launches a cascade of adipokine-
mediated metabolic, inflammatory and haemostasic disturbances accelerating the process of atherosclerosis.
Since each of these factors increases the global risk, the use of total cardiometabolic risk (CMR) is useful. There
are numerous software applications for estimation of CMR. In general, a scoring procedure based on score tables
is inapplicable for the analysis of complex and unconventional cases.
There has been much interest in the clinical use of artificial neural network (ANN) as a form of artificial
intelligence that has been used to simulate the human brain?s own problem-solving process and takes previously
solved examples and recognize complex patterns between inputs and outputs parameters. ANN inputs are values
gender, age, waist-to-height ratio, and body mass index, systolic and diastolic blood pressure. ANN output is
cardiometabolic risk-coefficient obtained from the number of disturbances in risk factors: HDL-, LDL- and total
cholesterol, triglycerides, glycemia, fibrinogen and uric acid. ANN training and testing are done by dataset that
includes 1281 persons, aged 18 to 67 years, with BMI values between 16.60 and 48.00 kg/m
. The accuracy of this
solution is 82.76%. The clinical application of artificial neural network could be a useful tool in both, individual
and public health prevention since it can be beneficial in identifying persons with increased cardiometabolic risk
in an easy?to-measure and non-invasive way.
Edita Stokic, M.D., Ph.D. is Endocrinologist and Professor of Internal medicine-Endocrinology, employed in the Clinic of Endocrinology,
Diabetes and Metabolic Disorders of the Clinical Centre of Vojvodina in Novi Sad, Serbia. In 2005, she was appointed as Chief
of Department. She is currently the vice president of Serbian Association for the Study of Obesity and chairman of the Continuing
Education Board (Society of Physicians of Vojvodina of the Medical Society of Serbia). She is also president of the Internal Medicine
Section, and (2002-2004) president of Endocrinology Section within same society. She is an author or co-author of 372 scientific
articles, and publications on obesity, dyslipidemias and diabetes. She has also published monograph Obesity is treatable disease.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals